Treatment of Irritable Bowel Syndrome in Adults
Begin with lifestyle modifications and soluble fiber, escalate to symptom-specific pharmacotherapy (loperamide for IBS-D, linaclotide for IBS-C, tricyclic antidepressants for refractory pain), and reserve psychological therapies for patients who remain symptomatic after 12 months of optimal medical management. 1, 2, 3
Step 1: Establish Diagnosis and Set Expectations
Make a positive diagnosis in patients under 45 years who meet Rome IV criteria (abdominal pain ≥1 day/week for ≥3 months associated with altered bowel habit) without alarm features—rectal bleeding, unintentional weight loss ≥5%, anemia, fever, nocturnal symptoms, or family history of colorectal cancer or inflammatory bowel disease—and avoid extensive testing. 1, 3
Explain to every patient that IBS is a gut-brain interaction disorder with a benign, relapsing-remitting course that does not progress to cancer or inflammatory bowel disease; this single conversation reduces anxiety, healthcare visits, and improves treatment adherence. 1, 3
Obtain celiac serology, complete blood count, and fecal calprotectin (in patients <45 years with diarrhea) to exclude organic disease; do not routinely test for food allergies, small intestinal bacterial overgrowth, or pancreatic insufficiency. 1
Step 2: Universal First-Line Interventions (All Patients)
Lifestyle Modifications
Prescribe regular aerobic exercise to all IBS patients as foundational therapy; physical activity independently improves global symptom scores across all subtypes. 1, 2, 3
Advise patients to limit excess caffeine and alcohol, allocate sufficient time for a regular morning bowel movement, and avoid unnecessary self-imposed dietary restrictions. 1, 3
Dietary Interventions
Start soluble fiber (psyllium/ispaghula) at 3–4 g daily and titrate upward gradually to minimize bloating; this regimen improves global IBS symptoms and abdominal pain across all subtypes. 1, 2, 3
Avoid insoluble fiber such as wheat bran, which consistently worsens bloating, abdominal pain, and overall symptom burden in all IBS subtypes. 1, 2, 3
Offer a 12-week trial of probiotics for global symptoms and abdominal pain; discontinue if no improvement occurs, noting that no single strain has proven superiority. 1, 3
Do not recommend IgG antibody-based food elimination diets or gluten-free diets unless celiac disease is confirmed by serology and biopsy; current evidence does not support their use in IBS. 1, 2, 3
Step 3: Symptom-Specific Pharmacotherapy
For Diarrhea-Predominant IBS (IBS-D)
Prescribe loperamide 2–4 mg up to four times daily (regular or prophylactic before outings) as first-line therapy to reduce stool frequency, urgency, and fecal soiling; titrate carefully to avoid constipation, bloating, or abdominal pain. 1, 2, 3
In patients with nocturnal diarrhea or history of cholecystectomy, test for bile acid malabsorption (SeHCAT scan or serum 7α-hydroxy-4-cholesten-3-one); if positive, treat with cholestyramine. 1
Add rifaximin 550 mg three times daily for 14 days as second-line therapy for global IBS-D symptoms; its effect on abdominal pain is limited. 1, 2
Avoid alosetron (5-HT3 antagonist) due to serious safety concerns, including risk of ischemic colitis. 1, 2
For Constipation-Predominant IBS (IBS-C)
If soluble fiber fails after 4–6 weeks, add polyethylene glycol (PEG) osmotic laxative and titrate to symptom response; abdominal discomfort is the most common adverse effect. 1, 3
Prescribe linaclotide 290 µg once daily on an empty stomach (≥30 minutes before the first meal) as the preferred prescription agent after first-line failure; high-quality trials demonstrate significant benefit for both constipation and abdominal pain (combined responder rate 12–13% vs 3–5% with placebo). 1, 3, 4
Counsel patients that diarrhea is the most common adverse event with linaclotide; review efficacy after 3 months and discontinue if no response. 1, 3, 4
Consider lubiprostone 8 µg twice daily with food as a conditional third-line option for women with IBS-C; nausea occurs in ~19% versus 14% with placebo. 1, 3
Do not prescribe anticholinergic antispasmodics (dicyclomine, hyoscyamine) in IBS-C, as they reduce intestinal motility and worsen constipation. 1, 3
For Abdominal Pain (All Subtypes)
Prescribe antispasmodics with anticholinergic properties (dicyclomine) taken before meals as first-line therapy for meal-related abdominal pain; counsel patients about dry mouth, visual disturbances, and dizziness. 1, 2, 3
Use peppermint oil as an alternative antispasmodic with a more favorable side-effect profile. 5, 1, 2, 3
Step 4: Neuromodulators for Refractory Pain or Mixed IBS
Prescribe tricyclic antidepressants (amitriptyline) as the most effective second-line treatment for global symptoms and abdominal pain across all IBS subtypes; start 10 mg nightly and titrate by 10 mg weekly to a target of 30–50 mg daily. 5, 1, 2, 3
Continue effective tricyclic therapy for at least 6 months before considering discontinuation if sustained improvement is reported. 5, 1, 2, 3
In IBS-C, ensure concurrent laxative therapy (PEG) when prescribing tricyclics to mitigate anticholinergic-induced worsening of constipation. 1, 3
If tricyclics are not tolerated or exacerbate constipation, prescribe selective serotonin reuptake inhibitors (SSRIs) as an alternative neuromodulator, although supporting evidence is weaker. 1, 3
Do not prescribe SSRIs solely for IBS-D, as pooled data from five randomized trials show no significant improvement in global relief or abdominal pain. 1
Step 5: Advanced Dietary Intervention for Refractory Symptoms
If symptoms persist after 4–6 weeks of first-line measures, refer to a trained dietitian for a supervised low-FODMAP diet delivered in three phases: restriction (4–6 weeks), systematic reintroduction, and personalized long-term maintenance. 1, 3, 6, 7, 8
Do not implement a low-FODMAP diet without intensive dietitian supervision, as unsupervised restriction may cause unnecessary dietary limitations and nutritional deficits. 1, 3
Step 6: Psychological Therapies for Persistent Symptoms
Offer IBS-specific cognitive-behavioral therapy (CBT) and gut-directed hypnotherapy when symptoms remain refractory after at least 12 months of optimal pharmacologic management; both modalities reduce overall symptom burden. 5, 1, 2, 3
Prioritize psychological therapies for patients whose symptoms are stress-related, associated with anxiety or depression, or of relatively short duration. 5, 1
Step 7: Monitoring and Referral
Assess treatment efficacy at 3 months; discontinue any therapy that does not provide meaningful benefit. 5, 1, 2, 3
Refer to gastroenterology when diagnostic uncertainty exists, alarm features are present, symptoms are severe or refractory after 12 weeks of first-line therapy, or the patient requests specialist input. 1, 3
Refer to a gastroenterology dietitian if the patient consumes considerable intake of IBS-trigger foods, exhibits dietary deficiencies, experiences unintended weight loss ≥5% in 6 months, or requests dietary counseling. 5, 3
Refer to a gastropsychologist if IBS symptoms are moderate to severe, the patient acknowledges gut-brain involvement, and has capacity to engage in coping-skill training. 5, 3
Critical Pitfalls to Avoid
Do not pursue extensive diagnostic testing in patients <45 years without alarm features; such testing reinforces illness anxiety and adds unnecessary cost without benefit. 1, 3
Do not prescribe opioid analgesics for chronic abdominal pain in IBS due to high risk of dependence, opioid-induced bowel dysfunction, and other complications. 5, 1, 2
Do not continue docusate (Colace) as it adds no benefit to other laxative therapy and lacks efficacy for constipation. 1
Do not prescribe anticholinergic antispasmodics (dicyclomine, hyoscyamine) for IBS-C based solely on the "IBS" diagnosis without considering the constipation subtype, as this will worsen constipation. 1, 3
Recognize that complete symptom resolution is often not achievable; the goal is symptom relief and improved quality of life, not cure. 1, 3